Trusopt®
Dorzolamide 2% · ophthalmic solution
Antiglaucoma
Approved uses
Elevated IOP in ocular hypertension or open-angle glaucoma
1 drop in the affected eye(s) TID
Peak IOP falls about 23% and afternoon trough about 17%, sustained over 1 year.
OFF-LABELNot in the FDA label for this product
Cystoid macular edema in retinitis pigmentosa
1 drop 2% TID in the affected eye(s)
Meta-analysis · nonrandomized
Meta-analysis of 11 nonrandomized clinical reports (194 patients, 358 eyes, of which 243 eyes received a topical carbonic anhydrase inhibitor) pooled oral and topical treatment and found central macular thickness fell 46.02 microns (95% CI 31.08 to 60.96), while the effect on visual acuity was inconsistent across studies. The authors state the anatomic benefit rests on nonrandomized data and call for randomized trials.
Foveal schisis in X-linked retinoschisis
1 drop 2% BID to TID in both eyes, long-term
Retrospective series · n=10
Retrospective interventional case series of 10 genetically confirmed patients (18 eyes) followed a mean 8.4 years: mean central subfield thickness went from 429.88 to 372.28 microns (P = 0.10, not significant) while mean logMAR acuity improved from 0.45 to 0.34 (P below 0.01). No randomized data exist, and paradoxical worsening of macular cysts on topical therapy has been reported in a single case.
Contraindications
Hypersensitivity to any component of this product
Ophthalmic solution, 5 mL in a 7.5 mL bottle, 10 mL in a 10 mL bottle, dorzolamide 2% (20 mg/mL)
Dorzolamide is an inhibitor of human carbonic anhydrase II. Inhibition of carbonic anhydrase in the ciliary processes decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. The result is a reduction in intraocular pressure. In healthy subjects given oral dosing that simulated topical exposure, inhibition of CA-II and total carbonic anhydrase activities stayed below the degree anticipated to be necessary for a pharmacological effect on renal function and respiration.
Warnings & Precautions
- Sulfonamide hypersensitivity: Dorzolamide is a sulfonamide and is absorbed systemically, so adverse reactions attributable to sulfonamides may occur. Fatalities have occurred, although rarely, due to severe sulfonamide reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia and other blood dyscrasias. Discontinue if signs of serious reactions or hypersensitivity occur. Sensitization may recur on readministration by any route.
- Corneal edema: There is an increased potential for corneal edema in patients with low endothelial cell counts. Use caution when prescribing to this group of patients.
- Allergic reactions: Local ocular adverse effects, primarily conjunctivitis and lid reactions, were reported with chronic use. Many had the appearance and course of an allergic-type reaction that resolved on discontinuation. If such reactions occur, discontinue and evaluate the patient before considering restarting the drug.
- Severe renal impairment: Not studied in severe renal impairment (CrCl < 30 mL/min). Not recommended in such patients, because dorzolamide and its metabolite are excreted predominantly by the kidney.
- Hepatic impairment: Not studied; use with caution.
- Additive systemic effects: There is a potential additive effect on the known systemic effects of carbonic anhydrase inhibition in patients also receiving an oral carbonic anhydrase inhibitor; concomitant use is not recommended.
- Acid-base and electrolyte disturbances: Not reported in clinical trials with dorzolamide, but reported with oral carbonic anhydrase inhibitors, in some instances resulting in drug interactions (e.g., toxicity with high-dose salicylate therapy). Consider the potential for such interactions.
- Contact lens use: Benzalkonium chloride may be absorbed by soft contact lenses; remove lenses before instillation. Lenses may be reinserted 15 minutes later.
- Acute angle-closure glaucoma: Management requires intervention beyond ocular hypotensive agents.
- Bacterial keratitis: Reported from contaminated multi-dose containers, mostly in eyes with concurrent corneal disease or epithelial disruption.
Common Side Effects
Ocular burning, stinging, or discomfort immediately following instillation occurred in approximately one-third of patients. Superficial punctate keratitis occurred in 10% to 15% of patients. Signs and symptoms of ocular allergic reaction occurred in approximately 10%; conjunctivitis and lid reactions occurred in approximately 1% to 5%. Blurred vision, eye redness, tearing, dryness and photophobia occurred in approximately 1% to 5%. Approximately one-quarter of patients noted a bitter taste; headache, nausea and asthenia/fatigue were reported infrequently. Skin rashes, urolithiasis and iridocyclitis were reported rarely. Postmarketing reports include Stevens-Johnson syndrome, toxic epidermal necrolysis, angioedema, bronchospasm, transient myopia, choroidal detachment following filtration surgery and eyelid crusting.
Pregnancy: No adequate and well-controlled studies in pregnant women. Oral dorzolamide caused fetal vertebral malformations in rabbits at 37 times the clinical exposure and was not teratogenic at up to 15 times; rat dosing in late gestation and lactation delayed offspring growth at 52 times.
Lactation: No human data on milk presence, effects on the breastfed infant, or milk production; drug and its N-desethyl metabolite are detected in the milk of lactating rats.
Safety and effectiveness have been demonstrated in pediatric patients in a 3-month, multicenter, double-masked, active-treatment-controlled trial.